HOXA7 promotes the metastasis of KRAS mutant colorectal cancer by regulating myeloid-derived suppressor cells
Cancer Cell International,
Abstract Background KRAS mutation accounts for 30–50% of human colorectal cancer (CRC) cases.
Abstract Background KRAS mutation accounts for 30–50% of human colorectal cancer (CRC) cases.
Cancer immunotherapy has a very long and somewhat torrid history, from the use of the eponymous Coley’s toxin in the 19th…